NCT00426608 - To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2006

Primary Completion Date

January 8, 2007

Study Completion Date

January 8, 2007

Conditions

Depressive Disorder and Anxiety Disorders

Interventions

DRUG

metyrapone

Metyrapone will be available as 250 mg dose capsule.

DRUG

alprazolam

Alprazolam capsules will be available with dose strength of 0.25mg

DRUG

placebo

GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

DRUG

GSK561679

GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.

Trial Locations (1)

CB2 0QQ

GSK Investigational Site, Cambridge